? Medix Biochemica簽署了收購(gòu)Lee Biosolutions 100%股權(quán)的最終協(xié)議，Lee Biosolutions是體外診斷行業(yè)的領(lǐng)先供應(yīng)商，可以提供大量不同的高質(zhì)量生物原料
Medix Biochemica has signed a definitive agreement to acquire 100 per cent of the shares in Lee Biosolutions, a leading provider of a large variety of high-quality biomaterials for the in vitro diagnostics industry
?本次并購(gòu)進(jìn)一步擴(kuò)充了Medix Biochemica在IVD原料領(lǐng)域的產(chǎn)品線，同時(shí)為Medix Biochemica在美國(guó)市場(chǎng)的進(jìn)一步增長(zhǎng)提供了一個(gè)強(qiáng)有力的平臺(tái)
The acquisition expands Medix Biochemica’s leading portfolio of bioreagents as well as provides Medix Biochemica with a strong platform for further growth in the US market
? Lee Biosolutions的CEO兼董事會(huì)主席Burton Lee先生將從日常業(yè)務(wù)中退出，并成為Medix Biochemica的高級(jí)顧問和股東
Burton Lee, the CEO and Chairman of Lee Biosolutions, will step down from daily operations and become a Senior Advisor and shareholder in Medix Biochemica
? Lee Biosolutions的總裁兼COO Matthew Lee先生將繼續(xù)領(lǐng)導(dǎo)Lee Biosolutions的運(yùn)營(yíng)
President and COO Matthew Lee of Lee Biosolutions will continue to head the operations of Lee Biosolutions
? 本次交易后，Medix Biochemica和Lee Biosolutions互補(bǔ)的產(chǎn)品線將可以通過全球銷售網(wǎng)絡(luò)提供給市場(chǎng)
As a result of the transaction, the complementary product portfolios of Medix Biochemica and Lee Biosolutions will be available from a comprehensive global sales network
Medix Biochemica簽署了收購(gòu)Lee Biosolutions 100%股權(quán)的最終協(xié)議，本次并購(gòu)進(jìn)一步擴(kuò)充了Medix Biochemica在IVD關(guān)鍵原料領(lǐng)域的產(chǎn)品線，并強(qiáng)化了其在美國(guó)市場(chǎng)力量。交易后，Lee Biosolutions將成為Medix Biochemica全球架構(gòu)下的運(yùn)營(yíng)中心之一，主要進(jìn)行IVD行業(yè)的生物原料業(yè)務(wù)。Lee Biosolutions的總裁兼COO，Matthew Lee，先生將帶領(lǐng)導(dǎo)運(yùn)營(yíng)，并向Medix Biochemica的CEO匯報(bào)。Lee Biosolutions的CEO及董事會(huì)主席，Burton Lee先生將在過渡期間繼續(xù)擔(dān)任高級(jí)顧問，作為本次交易的一部分，Burton Lee先生還將成為Medix Biochemica的股東之一。
Medix Biochemica has signed a definitive agreement to acquire 100 percent of the shares of Lee Biosolutions to broaden its portfolio of critical raw materials for the in vitro diagnostics (“IVD”) industry and strengthen its local presence in the US market. Following the transaction, Lee Biosolutions will become a Center of Excellence focused on biomaterials for the IVD industry within Medix Biochemica’s group structure. President and COO of Lee Biosolutions, Matthew Lee, will head its operations and report to the CEO of Medix Biochemica. CEO and Chairman of the Board of Lee Biosolutions, Burton Lee, will continue as Senior Advisor over a transition period and become a shareholder in Medix Biochemica as part of the transaction.
Lee Biosolutions成立于1975年，是一家為IVD行業(yè)提供高質(zhì)量蛋白、酶、抗原、及用于質(zhì)控和校準(zhǔn)品的生物試劑的生產(chǎn)商，并以其出眾的蛋白純化能力、以及原料供應(yīng)領(lǐng)域卓越的運(yùn)營(yíng)水平而知名。Lee Biosolutions的客戶遍布全球，覆蓋了全球最大的IVD生產(chǎn)商中的絕大部分，以及大量的制藥和醫(yī)療器械公司、研究所、法醫(yī)實(shí)驗(yàn)室。公司總部座落于美國(guó)密蘇里州圣路易斯市。
Founded in 1975, Lee Biosolutions is a manufacturer of high-quality proteins, enzymes, antigens and biologicals used for quality controls and calibrators in the IVD industry. The company is known for its outstanding capabilities in protein purification and operational excellence in raw materials sourcing. Lee Biosolutions’ customers include most of the largest global in vitro diagnostics manufacturers as well as a number of pharmaceutical and medical device companies, research institutions and forensic laboratories. The company is headquartered in St. Louis, Missouri.
“我們對(duì)于能與Lee Biosolutions成為伙伴而感到激動(dòng)，它在IVD行業(yè)作為高質(zhì)量的生物原料供應(yīng)商而享有盛名，并有強(qiáng)勁的財(cái)務(wù)表現(xiàn)。Lee Biosolutions和Medix Biochemica之間互補(bǔ)的產(chǎn)品線和區(qū)域架構(gòu)將使我們可以在未來更好地為我們?nèi)虻目蛻舴?wù)”，Medix Biochemica董事會(huì)主席Ann-Christine Sundell女士說道。
“We are excited about the partnership with Lee Biosolutions, which has gained a premium reputation as a provider of high-quality biomaterials for the IVD industry and achieved strong financial results. The complementary product offerings and regional presences of Lee Biosolutions and Medix Biochemica will enable us to serve our global customer base even better in the future”, says Ann-Christine Sundell, Chairman of the Board of Medix Biochemica.
“在Burton Lee先生的領(lǐng)導(dǎo)和主持下，Lee Biosolutions在過去幾十年建立了令人印象深刻的產(chǎn)品線、強(qiáng)大的客戶基礎(chǔ)、以及負(fù)責(zé)且經(jīng)驗(yàn)豐富的團(tuán)隊(duì)。這次合作是我們成為IVD關(guān)鍵原料領(lǐng)域第一選擇的偉大的第一步?！埃琈edix Biochemica副董事長(zhǎng)兼DevCo合伙公司合伙人Teemu Alahuhta表示。
“Lee Biosolutions has, under the leadership and ownership of Burton Lee, built an impressive product portfolio, strong customer base as well as committed and knowledgeable organization over the past decades. This partnership is a great first step in our pursuit to become the #1 choice for the IVD industry in critical raw materials “, says Teemu Alahuhta, Vice Chairman of the Board of Medix Biochemica and partner of DevCo Partners.
“我對(duì)于本次并購(gòu)、以及能與Medix Biochemica和DevCo合伙公司令人驚嘆的團(tuán)隊(duì)一起工作感到非常激動(dòng)。合并后我們將擁有成為IVD原料行業(yè)巨無霸所需的全部潛質(zhì)“，Lee Biosolutions 首席執(zhí)行官和董事會(huì)主席Burton Lee說。
“I am very excited about the acquisition and working with an incredible group of Medix Biochemica and DevCo Partners. Together we have all the capabilities to become a juggernaut in the IVD raw materials industry”, says Burton Lee, CEO and Chairman of Lee Biosolutions.
關(guān)于 Medix Biochemica
Medix Biochemica是世界領(lǐng)先的芬蘭生物技術(shù)公司，專注于為全球診斷市場(chǎng)提供高質(zhì)量的診斷用原料和快速檢測(cè)試劑。我們?yōu)轶w外診斷行業(yè)、包括頂級(jí)跨國(guó)IVD公司、開發(fā)、生產(chǎn)和銷售抗體、抗原并提供抗體服務(wù)。每年，我們的MedixMAB?抗體被使用于全世界數(shù)十億人份的診斷產(chǎn)品中，以保證其結(jié)果的精準(zhǔn)?，F(xiàn)在，Medix Biochemica的客戶遍布全球60多個(gè)國(guó)家，其90%的銷售額來自芬蘭以外的國(guó)際市場(chǎng)。公司總部位于芬蘭埃斯波，在美國(guó)和中國(guó)設(shè)有全資子公司。Medix Biochemica is a leading Finnish biotechnology company focusing on high quality diagnostic raw materials and rapid tests for global diagnostic markets. We develop, produce and market antibodies, antigens and antibody services for the in vitro diagnostics (IVD) industry and serve the largest multinational IVD companies. Our MedixMAB? antibodies are in use in billions of diagnostic tests all around the world to ensure accurate diagnostic results. Medix Biochemica’s products are used in over 60 countries with 90% of our sales coming from global markets. The company is headquartered in Espoo, Finland with local offices in the USA and China.
如有任何問題，請(qǐng)聯(lián)系Medix中國(guó)全資子公司
上海墨迪斯醫(yī)療技術(shù)有限公司
上海市浦東新區(qū)天雄路588弄21幢402
電話:021-68119180,68119105,68119181
郵箱:medixchina@medixbiochemica.com
中文網(wǎng)址:cnmedixbiochemica.com